Document ID: chunk:federal_register_of_legislation:F2022L01113:reg:9:p1
Version: federal_register_of_legislation:F2022L01113
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3989–6980

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting mature B-cell lymphoid leukaemia and small lymphocytic lymphoma or death from mature B-cell lymphoid leukaemia and small lymphocytic lymphoma with the circumstances of a person's relevant service:
(1)          being exposed to benzene as specified:
(a)          for a cumulative total of at least 2,500 hours within a continuous period of 5 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma; and
(b)          where the first exposure in that period occurred at least 5 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma;

Note: being exposed to benzene as specified is defined in the Schedule 1 - Dictionary
(2)          being exposed to benzene:
(a)          in an amount greater than 10 ppm-years of cumulative exposure before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma; and
(b)          where the first exposure occurred at least 5 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma;
Note: ppm-years is defined in the Schedule 1 - Dictionary.
(3)          having chronic infection with hepatitis C virus before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma;
             Note 1: In the past, hepatitis C viral infection may have been classified as non-A, non-B hepatitis.
Note 2: chronic infection with hepatitis C virus is defined in the Schedule 1 - Dictionary.
(4)          inhaling ethylene oxide vapour as specified:
(a)          for a cumulative total of at least 2,500 hours within a continuous period of 10 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma; and
(b)          where the first exposure in that period occurred at least 5 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma;
Note 1: Inhalation of ethylene oxide vapour can occur during the sterilisation of surgical instruments or protective clothing in hospitals.
Note 2: Inhaling ethylene oxide vapour as specified is defined in the Schedule 1 - Dictionary.
(5)          inhaling ethylene oxide vapour:
(a)          in an amount greater than 10 ppm-years of cumulative exposure before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma; and
(b)          where the first exposure occurred at least 5 years before the clinical onset of mature B-cell lymphoid leukaemia or small lymphocytic lymphoma;
Note 1: Inhalation of ethylene oxide vapour can occur during the sterilisation of surgical instruments or protective clothing in hospitals.
Note 2: ppm-years is defined in the Schedule 1 - Dictionary.

(6)          having received a cumulative equivalent dose of at least 0.1 sievert of